LENZ LENZ Therapeutics, Inc.

Nasdaq lenz-tx.com


$ 38.29 $ -2.19 (-5.41 %)    

Friday, 17-Oct-2025 15:59:56 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 38.26
$ 39.85
$ 37.70 x 200
$ 43.70 x 120
$ 37.65 - $ 39.94
$ 16.54 - $ 50.40
629,740
na
1.09B
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-19-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-20-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-21-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target fro...

Core News & Articles

VIZZ sample distribution initiated nationwide to Eye Care ProfessionalsCommercial product shipments to be initiated in October ...

Core News & Articles

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price t...

 lenz-therapeutics-eye-drop-scores-first-fda-approval-for-age-related-blurred-vision-condition-impacting-128-million-people

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch exp...

Core News & Articles

Citigroup analyst Yigal Nochomovitz maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price target from $4...

Core News & Articles

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition imp...

Core News & Articles

Raymond James analyst Gary Nachman maintains LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target f...

Core News & Articles

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0...

Core News & Articles

LENZ Therapeutics, Inc. (NASDAQ:LENZ, "LENZ" or the "Company"))), a pre-commercial stage biopharmaceutical comp...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and raises the price t...

Core News & Articles

LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Laboratoires Théa ("Théa") announced an exclusive license and commercializati...

Core News & Articles

HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Buy and maintains $38 pri...

Core News & Articles

LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION